“akero-therapeutics” Archives

in
Entry Author Date Location
Reeling From FDA Rejection, Intercept Pharma Slashes Headcount by 25% 09/01/20 New York
Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs 06/05/20 Boston
Akero Heads to Top of Class in NASH; Genfit Says Pandemic Won’t Delay Data 04/10/20 National
VenBio Partners Bags $394M to Back More Medicine-Making Biotechs 04/03/20 Boston
Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More 06/21/19 National
Four More Through the IPO Door as Life Science Firms Raise $465M 06/20/19 National
Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More 05/31/19 National
The Biotech IPO Queue Grows Longer as Five More Companies File 05/28/19 National
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) 12/18/18 National
Bio Roundup: Eli Lilly Tries Tau, Generic Insulin, NASH Cash & More 12/14/18 National
Roche Gains Place in NASH Race with Purchase of Jecure Therapeutics 11/27/18 San Francisco
89Bio Joins NASH Chase with a Teva Drug and $60M in Funding 10/25/18 San Francisco
Viking Liver Drug Shows Promise for NASH, Shares Soar on Study Data 09/18/18 San Diego
Bio Roundup: Big Bucks For Calico, Data Dumps & The IPO Wave Rolls On 06/29/18 National
Akero Closes $65M Financing to Back Liver Drug Licensed from Amgen 06/25/18 Boston
Page 1 of 1